Completed PHASE4 INTERVENTIONAL 2-arm NCT01250652

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (LevoHydroxy)

Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study

Sponsor: Association Asthma, Bulgaria

Conditions Chronic Urticaria

Interventions Levocetirizine Levocetirizine plus Hydroxyzine

Updated 5 times since 2017 Last updated: Jul 15, 2013 Started: Mar 31, 2011 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Urticaria and is currently completed. Association Asthma, Bulgaria leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Association Asthma, Bulgaria
UCB Pharma

Data source: Association Asthma, Bulgaria

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sofia, Bulgaria